{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:29:56Z","timestamp":1786480196793,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"DOI":"10.13039\/501100007638","name":"Kidney Foundation, Japan","doi-asserted-by":"crossref","award":["JKFB17-9"],"award-info":[{"award-number":["JKFB17-9"]}],"id":[{"id":"10.13039\/501100007638","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,8]]},"abstract":"\n Background<\/jats:title>\n The development and prompt dissemination of the first drug against a particular disease can contribute to improvements in national health status and medical economy end points and are assumedly affected by socioeconomic factors that have yet to be analyzed. Tolvaptan, a vasopressin receptor 2 antagonist, was developed to treat hyponatremia, congestive heart failure, and cirrhosis ascites, although the approved indications may differ among countries. In Japan, high-dose tolvaptan tablets were approved as the first drug for autosomal dominant polycystic kidney disease (ADPKD) in 2014. This study aimed to better understand the factors that influence the total number of regional prescriptions of tolvaptan for ADPKD since its launch.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The National Database of Health Insurance Claims and Specific Health Checkups of Japan Open Data was used as a national claim-based database. In each of the 47 prefectures in Japan, the total prescribed number of 30 mg tolvaptan tablets between 2015 and 2017 was examined. The parameters explaining the prescription variation among regions were then examined by correlation analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Prescriptions for high-dose tolvaptan increased substantially 2 years after the drug\u2019s approval; however, the increase differed by approximately 21-fold between regions. Population density was positively associated with prescribed 30 mg tolvaptan tablets per 1000 population in 2015 (\n r<\/jats:italic>\n =0.47,\n P<\/jats:italic>\n <0.001). In addition, the increase in prescribed number of tablets per 1000 population was correlated with population density in 2016\u20132017 (\n r<\/jats:italic>\n =0.30,\n P<\/jats:italic>\n =0.04).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This macro perspective analysis revealed an urban-rural inequity in prescriptions for the newly approved drug for ADPKD. Further studies are needed to elucidate the factors affecting the geographic variation.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0002262020","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T21:49:37Z","timestamp":1592344177000},"page":"740-745","source":"Crossref","is-referenced-by-count":9,"title":["Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.34067","volume":"1","author":[{"given":"Reiko","family":"Inoue","sequence":"first","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Mitsui Memorial Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Honda","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2125.2001.01332.x","article-title":"Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message","volume":"51","author":"McGettigan","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12913-019-3889-4","article-title":"Factors affecting general practitioners\u2019 decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1472-6963-12-56","article-title":"Adoption of new drugs by physicians: A survival analysis","volume":"12","author":"Garj\u00f3n","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.sapharm.2009.09.003","article-title":"Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing","volume":"6","author":"Groves","year":"2010","journal-title":"Res Social Adm Pharm"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/fampra\/20.1.61","article-title":"Influences on GPs\u2019 decision to prescribe new drugs-the importance of who says what","volume":"20","author":"Prosser","year":"2003","journal-title":"Fam Pract"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ackd.2010.01.003","article-title":"Extrarenal manifestations of autosomal dominant polycystic kidney disease","volume":"17","author":"Pirson","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ekir.2016.09.061","article-title":"The longitudinal study of liver cysts in Patients with autosomal dominant polycystic kidney disease and polycystic liver disease","volume":"2","author":"Matsuura","year":"2016","journal-title":"Kidney Int Rep"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejrad.2017.10.023","article-title":"Patterns of CT use in Japan, 2014: A nationwide cross-sectional study","volume":"97","author":"Koyama","year":"2017","journal-title":"Eur J Radiol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00296-017-3900-5","article-title":"Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using \u201cNational Database of Health Insurance Claims and Specific Health Checkups of Japan\u201d","volume":"38","author":"Kamata","year":"2018","journal-title":"Rheumatol Int"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11604-018-0724-5","article-title":"Global and Japanese regional variations in radiologist potential workload for computed tomography and magnetic resonance imaging examinations","volume":"36","author":"Kumamaru","year":"2018","journal-title":"Jpn J Radiol"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13561-019-0238-6","article-title":"National burden of the pharmaceutical cost of wet compresses and its cost predictors: Nationwide cross-sectional study in Japan","volume":"9","author":"Itoh","year":"2019","journal-title":"Health Econ Rev"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10157-019-01720-x","article-title":"Regional variance in patterns of prescriptions for chronic kidney disease in Japan","volume":"23","author":"Inoue","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"B17-20230821","article-title":"Regional variance in the use of urine dipstick test for outpatients in Japan [published online ahead of print April 3, 2020]","author":"Nishi","journal-title":"Nephrology (Carlton)"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00005650-200308000-00004","article-title":"Physician and practice characteristics associated with the early utilization of new prescription drugs","volume":"41","author":"Tamblyn","year":"2003","journal-title":"Med Care"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10198-011-0311-5","article-title":"In with the new: The determinants of prescribing innovation by general practitioners in Ireland","volume":"13","author":"Bourke","year":"2012","journal-title":"Eur J Health Econ"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: A systematic literature review","volume":"14","author":"Lubl\u00f3y","year":"2014","journal-title":"BMC Health Serv Res"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002262020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:57:00Z","timestamp":1786478220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002262020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0002262020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}